Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.61 |
| ▸ | HCN1 | O60741 | 9/20 | 0.54 |
| ▸ | HCN4 | Q9Y3Q4 | 8/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233235 | 0.94 | SLC6A5 (0.62) | SLC6A5HCN1HCN4ALDH1A1HTR2A | |
| SCHEMBL16233232 | 0.91 | SLC6A5 (0.70) | SLC6A5HCN1HCN4TP53ALDH1A1 | |
| SCHEMBL16233193 | 0.89 | HCN1 (0.53) | SLC6A5HCN1HCN4TP53 | |
| SCHEMBL16234614 | 0.85 | SLC6A5 (0.72) | SLC6A5HCN1HCN4TP53ALDH1A1 | |
| SCHEMBL16233178 | 0.84 | TP53 (0.60) | HCN1HCN4TP53ALDH1A1 | |
| SCHEMBL16233163 | 0.83 | SLC6A5 (0.83) | SLC6A5TP53ALDH1A1HTR2AP2RX3 | |
| SCHEMBL16233181 | 0.83 | TDP1 (0.49) | SLC6A5HCN1HCN4ALDH1A1 | |
| SCHEMBL16234616 | 0.80 | SLC6A5 (0.63) | SLC6A5ALDH1A1HTR2AP2RX3 | |
| SCHEMBL16233224 | 0.80 | HCN1 (0.61) | SLC6A5HCN1HCN4TP53 | |
| SCHEMBL16233231 | 0.79 | TSHR (0.64) | SLC6A5TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | SLC6A5 1714/4885HCN1 253/4885HCN4 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.